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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective is to assess the effects of any intervention and determine the effect of timing of any intervention in the treatment
of strabismus, gaze deficits and nystagmus due to acquired brain injury in order to align visual axes in primary and/or secondary gaze
positions.
The secondary objectives will be to determine whether in patients with eye movement disorders due to acquired brain injury, at what
time point or period, using the following interventions and comparators.
• Restitutive treatment is more effective than control, placebo, alternative treatment or no treatment in improving ocular
alignment and/or motility.
• Substitutive treatment is more effective than control, placebo, alternative treatment or no treatment in improving ocular
alignment and/or motility.
• Compensatory treatment is more effective than control, placebo, alternative treatment or no treatment in improving ocular
alignment and/or motility.
• Pharmacological treatment is more effective than control, placebo, alternative treatment or no treatment in improving ocular
alignment and/or motility.
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B A C K G R O U N D
Description of the condition
Acquired brain injury is brain damage caused by events caused af-
ter birth that result in permanent or temporary changes in cogni-
tion, physical, emotional and behavioural function. This may be
due to trauma, surgery, stroke, brain tumour, infection, inflamma-
tion and ischaemia. Eye movement disorders following acquired
brain injury may include strabismus, gaze deficits and nystagmus
(Rowe 2003). In acquired brain injury, these eye movement dis-
orders are caused by damage to the cranial nerves that supply the
extra ocular muscles or to damage of the neurological areas that
contribute to the control of eye movements (Pierrot-Deseilligny
2011). It is unknown what the incidence of visual problems is
for acquired brain injury but estimates are available for certain
types of acquired brain injury. For example, over half of stroke sur-
vivors have visual impairments (Freeman 1988), and up to 68%
of stroke survivors with visual symptoms have eye movement dis-
orders (Rowe 2009). These impact on daily life by causing a range
of difficulties including inability to maintain normal ocular align-
ment or move the eyes appropriately (Jones 2006; Pedersen 1981;
Rowe 2011a). Functional disabilities occur including loss of depth
perception, reduced hand-eye coordination and reading impair-
ment (MacIntosh 2003; Rowe 2011b), and these may impede the
effectiveness of rehabilitation therapy in regaining mobility, activ-
ities of daily living and quality of life (Ciuffreda 2007; MacIntosh
2003).
The true incidence of eyemovement disorders in acquired brain in-
jury is unknown and the prevalence varies depending on the cause
of brain injury and area of brain involved. Strabismus is a deviation
of the ocular alignment where one eye turns and which may be
intermittent or constant (Fowler 1996; Rowe 2010). Strabismus
occurs in a number of forms including esotropia (in-turning de-
viation), exotropia (out-turning deviation) or less commonly, hy-
pertropia (up-turning deviation), hypotropia (down-turning de-
viation) and cyclotropia (rotatory deviation). Gaze deficits include
disorders of the eyemovement systemswhich involve saccades (fast
movements of the eyes), smooth pursuits (slow, tracking move-
ments of the eyes), vergence (opposite movements of the eyes such
as convergence where both eyes turn inwards symmetrically or
divergence where both eyes turn outwards), cranial nerve palsy
(impairment of III, IV or VI nerve function causing abnormal
eye movement and strabismus in the affected eye), bilateral gaze
palsy (impaired horizontal, vertical or combined movements in
both eyes), unilateral gaze palsy (internuclear ophthalmoplegia,
one and a half syndrome) and vestibulo-ocular and opto-kinetic
reflexes (involuntary movements of the eyes in response to mov-
ing objects and movement of the head and body) (Pedersen 1981;
Rowe 2011a; Rowe 2013a). Nystagmus is a condition in which
there are frequent involuntary oscillations of the eyes that result
in reduced visual function (Rowe 2008).
Symptoms of eye movement disorders can include blurring of vi-
sion, diplopia (double vision), impaired depth (3-dimensional)
perception, wobbling and jumbling of images, and reading diffi-
culty (Rowe 2013b).
Description of the intervention
There are various treatments associatedwith strabismus, eyemove-
ment disorders and nystagmus. Primarily, treatment is directed at
aligning the visual axes and improving the movement of the eyes.
Treatments for eye movement disorders can be described as resti-
tution, compensation, substitution or pharmacology (Kerkhoff
2000; Pollock 2011). Restitutive interventions may include con-
vergence training, pursuit training and saccade training. Compen-
sative interventions may include training eye movements for read-
ing, compensatory head posture or movements, use of eye blinks
or colour cues and training in activities of daily living. Substitutive
interventions may include prisms, eye patches, lens alteration, bo-
tulinum toxin and local anaesthetic injections, extra ocular mus-
cle surgery, magnification and environmental modification. Phar-
macological interventions may include prescription drugs such as
baclofen, memantine and carbamazepine.
Timing of treatment is dependent on the type of treatment op-
tion. Treatment options that can be provided early after onset
include prisms, eye patches, botulinum toxin, exercises/training
programmes, magnifiers and compensatory head posture advice.
Treatment options that are provided at later stages (due to a re-
quirement of stable ocular measurements) include extra-ocular
muscle surgery and pharmacological drugs.
Commencement of interventions can be at multiple time points.
Where an individual is referred immediately following the occur-
rence of the eye movement disorder, interventions such as prisms
or occlusive eye patches to alleviate or reduce visual symptoms can
be provided straight away after diagnosis and appropriate mea-
surement of the disorder. Early treatment is considered to occur
within one week of onset of eye movement disorder. Where there
is a delay in referral, individuals may subconsciously close one
eye or turn their head in an attempt to compensate for their vi-
sual deficit. Furthermore, interventions such as botulinum toxin
and extra-ocular muscle surgery may be appropriate at later time
points.
How the intervention might work
Restitution
Restitution includes the biochemical events that help restore func-
tional neural tissue through the reductionof oedema, absorptionof
blood, restoration of normal neuronal physiology, and restoration
of axon transport (Pollock 2011). Treatments of positive fusional
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amplitudes and stereopsis through repetition training of specific
deficient functions, such as convergence insufficiency, have been
reported as effective (Kerkhoff 2000). Restitutive interventions
will include those where there is direct training of the impaired
function or repetitive stimulation of eye movement.
Compensation
Compensation aims to improve the mismatch between the pa-
tients’ skills and the demands placed on them by their environ-
ment, by teaching patients to compensate or adapt using a spared
or intact function (Kerkhoff 1999; Kerkhoff 2000).
Substitution
Substitution involves adaptation of visual components that have
been lost or disrupted through the use of optic devices, extra-
ocular muscle surgery or environmental modifications (Kerkhoff
1999; Kerkhoff 2000).
Pharmacology
Pharmacology aims to improve visual functioning through alter-
ation of biochemical and/or physiological effects in the body.
Why it is important to do this review
There aremany forms of interventions for eyemovement disorders
that occur following acquired brain injury. Although the natural
history of acquired brain injury differs dependent on the cause,
the treatment of the resultant eye movement disorder is princi-
pally the same regardless of cause. Although the cause may recover
or progress, the resultant eye movement disorder may persist and
requires treatment to alleviate or reduce visual symptoms. We will
consider all interventions for all types of eye movement disorders
regardless of cause and evolution of eye movement disorder. We
will extract data for improving, stable or deteriorating eye move-
ment disorders. In the early stages, treatment may include conser-
vative options such as eye patching or prisms which are used whilst
the eye movement disorder is monitored until it improves or sta-
bilises. Where eye movement disorders persist, further treatment
options such as botulinum toxin or extra-ocular muscle surgery
may then be considered.
There are multiple time points at which interventions for eye
movement disorders that occur following acquired brain injury
may be provided. The timing of provision of treatment for eye
movement disorders differs for the various treatment options. In
the early stages, treatment may include conservative options such
as eye patching or prisms which are used whilst the eye movement
disorder is monitored until it improves or stabilises. Where eye
movement disorders persist, further treatment options such as bo-
tulinum toxin or extra ocular muscle surgery may then be con-
sidered. There can be delays in referral of patients with acquired
brain injury to eye care services and thus patients may not receive
treatment early even though treatment options are available. This
delay may impede general rehabilitation.
A recent systematic review on interventions for eyemovement dis-
orders in stroke found insufficient evidence to reach conclusions
about the effectiveness of those interventions for this group of pa-
tients (Pollock 2011). There was an absence of relevant evidence
with a recommendation for urgent high quality research. Further-
more, there is no consensus for what constitutes the optimum
timing for commencing interventions for eye movement disorders
due to stroke. Timing may vary dependent on the type of treat-
ment being considered (e.g. eye patch versus extra-ocular muscle
surgery) and/or the extent of visual symptoms (minimal versus se-
vere impact on daily life). Because this review only concentrated on
stroke populations, one recommendation was for a systematic re-
view of interventions for eye movement disorders in patients with
acquired brain injury in order to synthesise the current evidence
base, to guide current practice and aid in the development of well-
designed randomised controlled trials (RCTs). Other publications
reporting efficacy and timing of interventions for eye movement
disorders include populations with varied causes of brain damage
such as tumours, inflammation, infection, stroke and metabolic
causes.
Purpose
We propose to undertake a high-quality systematic review of the
existing evidence base in order to determine the evidence for effec-
tiveness and timing of any treatment or management approaches
for all adult patients with acquired brain injury with eye move-
ment disorders. This review will directly address the recommen-
dations of the Cochrane systematic review on interventions for
eye movement disorders in stroke (Pollock 2011), i.e. conduct a
systematic review of interventions for eye movement disorders in
patients with acquired brain injury in order to synthesise the cur-
rent evidence base, and whether the timing of interventions for
eyemovement disorders has an impact on objective and subjective
measures of ocular alignment and motility. This will guide current
practice and aid in the development of well-designed RCTs which
follow the U.K. Medical Research Council guidance on develop-
ing and evaluating complex interventions (Craig 2008).
O B J E C T I V E S
The primary objective is to assess the effects of any intervention
and determine the effect of timing of any intervention in the treat-
ment of strabismus, gaze deficits and nystagmus due to acquired
brain injury in order to align visual axes in primary and/or sec-
ondary gaze positions.
3Interventions for eye movement disorders due to acquired brain injury (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The secondary objectives will be to determine whether in patients
with eyemovement disorders due to acquired brain injury, at what
time point or period, using the following interventions and com-
parators.
• Restitutive treatment is more effective than control,
placebo, alternative treatment or no treatment in improving
ocular alignment and/or motility.
• Substitutive treatment is more effective than control,
placebo, alternative treatment or no treatment in improving
ocular alignment and/or motility.
• Compensatory treatment is more effective than control,
placebo, alternative treatment or no treatment in improving
ocular alignment and/or motility.
• Pharmacological treatment is more effective than control,
placebo, alternative treatment or no treatment in improving
ocular alignment and/or motility.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include RCTs and quasi-RCTs.
Types of participants
We will include individuals with eye movement disorders due to
acquired brain injury. The type of eye movement disorder may
include III, IV, and VI cranial nerve palsy, reduced fixation, gaze
holding, horizontal and/or vertica gaze palsy, internuclear ophthal-
moplegia, one and a half syndrome, saccadic problems, smooth
pursuit problems, strabismus, nystagmus, reduced convergence or
divergence, conjugate deviation and skew deviation. The devia-
tion of eye movement may be horizontal, vertical, torsional and
the severity of eye movement disorder may be slight, small, mod-
erate, marked, and paralysis, paresis; monocular, binocular.
We will accept studies that included participants based on symp-
toms which can be assumed to be present as a direct result of an
eye movement disorder. Symptoms may include double vision,
blurred vision, reading difficulty, wobbling or jumbled vision and
excessive headmovements.Wewill consider participants of all ages
from studies of adults and children.
Types of interventions
We will include any intervention that aims to improve the de-
fects of eye movement, or alleviating/reducing the visual symp-
toms associated with the disorder. We will classify interventions
as restitution, compensation pharmacological or substitution. We
will include any study that documented the timing (recorded as
time period from the onset of eye movement disorder) of any in-
tervention that aims to improve the defects of eye movement, or
alleviating/reducing the visual symptoms associated with the dis-
order. We will classify timing as early or late intervention where
early constitutes intervention within one month of eye movement
disorder onset.
Types of outcome measures
Where possible, we will assess outcome as a dichotomous variable
(yes/no) at the end of the intervention period and at a follow-up
point (ideally a minimum of three months after the completion
of the intervention and maximum of 12 months).
Primary outcomes
• Improvement in ocular motility measured by orthoptic
assessments of reduction in the angle of deviation (within 10
prism dioptres of ortho) and/or extent of eye movement range
(improvement of one or more grades of limitation ranging from
1 to 4), such that visual axes are aligned in primary and/or
secondary gaze positions
Secondary outcomes
• Achievement of binocular single vision as assessed by cover
test, motor fusional vergences and stereoacuity
• Reduction of, or alleviation of, patient-reported symptoms
assessed by patient record notes or questionnaire
• Improvement in functional ability measured by validated
measures such as activity of daily living questionnaires
• Adverse events
◦ Intractable permanent diplopia, perforating injury,
symptomatic over or under correction, death
◦ Assessed by descriptive documentation
• Quality of life data
◦ Any measure of patient or parent satisfaction relating
to improvement in appearance or improvement to lifestyle
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled
Trials (CENTRAL) (which contains the Cochrane Eyes and
Vision Group Trials Register) (latest issue), Ovid MEDLINE,
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Ovid MEDLINE In-Process and Other Non-Indexed Citations,
Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946
to present), EMBASE (January 1980 to present), Cumula-
tive Index to Nursing and Allied Health Literature (CINAHL)
(1982 to present), Allied and Complementary Medicine Database
(AMED) (1985 to present), PsycINFO (1967 to present), Dis-
sertations & Theses (PQDT) database (1861 to present) (
http://pqdtopen.proquest.com/search.html), PsycBITE (Psycho-
logical Database for Brain Impairment Treatment Efficacy) (
http://www.psycbite.com/search.php), the metaRegister of Con-
trolled Trials (mRCT) (www.controlled-trials.com), ClinicalTri-
als.gov (www.clinicaltrial.gov), Health Services Research Projects
in Progress (HSRProj)
(wwwcf.nlm.nih.gov/hsr_project/home_proj.cfm), National Eye
Institute Clinical Studies Database (clinicalstudies.info.nih.gov/
cgi/protinstitute.cgi?NEI.0.html) and the World Health Organi-
zation (WHO) InternationalClinical TrialsRegistry Platform (IC-
TRP) (www.who.int/ictrp/search/en). We will not use any date or
language restrictions in the electronic searches for trials.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), CINAHL (Appendix 4), AMED (Appendix 5), PsycINFO (
Appendix 6), PQDTdatabase (Appendix 8), PsycBITE (Appendix
8), mRCT (Appendix 9), ClinicalTrials.gov (Appendix 10), HSR-
Pro (Appendix 11), National Eye Institute Clinical Studies
Database (Appendix 12) and the ICTRP (Appendix 13).
Searching other resources
We will search the reference lists of included trials to identify any
further studies andwill check the references of review articles about
vision after acquired brain injury. We will perform citation track-
ing using Web of Science Cited Reference Search for all included
studies and will contact experts in the field - including authors of
included trials, and excluded studies identified as possible prelim-
inary or pilot work. We will also search reference material sup-
plied by commercial companies who provide interventions aimed
at restoration of eye movements.
We will handsearch the following resources from their inception
to the current date at (http://pcwww.liv.ac.uk/~rowef/index_files/
Page646.htm):
• British and Irish Orthoptic Journal
• Australian Orthoptic Journal
• Proceedings of the European Strabismological Association
(ESA)
• International Strabismological Association (ISA)
• International Orthoptic Association (IOA)
Data collection and analysis
Wewill followguidance inChapter 7 of theCochrane Handbook for
Systematic Reviews of Interventions for data collection and Chapter
9 of the Cochrane Handbook for Systematic Reviews of Interventions
for data analysis (Deeks 2011; Higgins 2011a), and also conform
to the PreferredReporting Items for Systematic Reviews andMeta-
Analyses (PRISMA) checklist (Moher 2009). The Cochrane Eye
and Vision Group Trials Search Co-ordinator will run all the elec-
tronic searches, download references into bibliographic software,
and remove duplicates. Two review authors will exclude any titles/
abstracts which are obviously not related to acquired brain injury
and vision. They will independently consider each of these titles/
abstracts and exclude any studies where the intervention is not
specifically aimed at improving the eye movement disorder or the
patient’s ability to cope with the eye movement disorder. We will
resolve any disagreements through discussion. We will obtain the
full papers for any studies included at this stage.
Selection of studies
Two review authors will independently apply the selection criteria,
considering and documenting the type of studies, type of partic-
ipants, intervention, comparison intervention, and the outcome
measures. Each review author will classify each study as include
or exclude. If there is disagreement between these two review au-
thors, they will reach consensus through discussion involving a
third review author.
We will list all excluded studies that included participants with eye
movement disorders in the ’Characteristics of excluded studies’
table with the reasons for exclusion. We will not list studies in
the ’Characteristics of excluded studies’ table that are excluded
because they includedparticipants that did not have eyemovement
disorders (i.e. visual neglect, age-related visual problems, or visual
field loss), unless the two review authors agree that there is a clear
reason to do so.
Data extraction and management
We will use a pre-designed data extraction form to record data
from the included studies. Two review authors will independently
document information found in the table in Appendix 14. If there
are any discrepancies between data extracted by the two review
authors, they will resolve these through discussion.
Assessment of risk of bias in included studies
Wewill follow theCochraneCollaboration tool for assessing risk of
bias for randomised trials as outlined in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b).
We will assess sequence generation, allocation concealment, mask-
ing (blinding) of participants, personnel and outcome assessors,
incomplete outcome data, selective outcome reporting and other
sources of bias. We will judge each domain as “low risk of bias”,
“high risk of bias” or “unclear”.
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Measures of treatment effect
We will use the Cochrane Collaboration statistical software,
Review Manager 2014, to carry out statistical analyses to deter-
mine the treatment and timing effect of restitutive, compensatory,
substitutive and pharmacological interventions.
The outcomemeasures of angle of deviation, range of ocularmove-
ments and binocular vision measures versions comprise of either
ordinal data frommeasurement scales (e.g. prism dioptre measure-
ments), count data (e.g. movement grading scales of 1 to 4, -1 to -
4), or continuous data (e.g. degree measurements). The threshold
for reduction in angle of deviation is +/- 10 prism dioptres (5 de-
grees) of ortho and for reduction of ocular movements is +/1 one
grade. We will analyse these as continuous variables.
Where change (improvement) is reported for angle of deviation,
range of ocular movements and binocular vision measures, we
will analyse this as dichotomous data with yes/no for reports of
improvement.
If reported outcomes have a scale which uses negative values (e.g.
divergent ocular deviations recorded as “-”), we will multiply the
reported values by -1, so that in all analyses the results are repre-
sented as positive values.
If studies report change values and the baseline value is available,
we will calculate the value at follow-up (change value - baseline
value). If studies report change values and the baseline value is
available, we will use these data in meta-analyses, but we plan to
conduct sensitivity analyses to investigate the effect of including
these data.
Wewill analyse adverse events and death as dichotomous variables.
For dichotomous variables, we will calculate the treatment effects
using a fixed-effect model (where there is a small number of trials
and where heterogeneity has not been detected) and report as odds
ratios (ORs) with 95% confidence intervals (CIs). For continuous
data, wewill calculate the treatment effect using standardisedmean
differences (SMDs) and 95% CIs where studies used different
scales for the assessment of the same outcome. We will use mean
differences (MDs) and 95% CIs where studies have all used the
same method of measuring outcome.
Unit of analysis issues
The above interventions will normally be applied at individual
level. Some interventions (e.g. prisms for diplopia or field defect,
monocular occlusion) are used to treat only one eye. In these in-
stances, there is no unit of analysis issue as the unit of randomi-
sation is the same as the unit of analysis. However, some inter-
ventions (e.g. scanning eye exercises, extra-ocular muscle surgery,
pharmacological interventions) treat both eyes. In these instances
we will report for the person through binocular measurements
such as binocular visual acuity, binocular single vision and binoc-
ular visual field.
Dealing with missing data
If an included study does not report a particular outcome, we will
not include that study in the analyses of that outcome. If an in-
cluded study has missing data (e.g. it reports the mean but not
standard deviations for the follow-up data) we will take logical
steps to enter an assumed value. Such steps may include calcu-
lating a standard deviation based on a reported standard error,
or estimating a follow-up standard deviation based on a baseline
value. We plan to do sensitivity analyses to investigate the effect of
entering assumed values. Where possible we will contact authors
to enquire about missing data to determine differences between
groups because of withdrawals, drop-outs and protocol deviations
and the extent of this for numbers across the groups, differences
across the groups and whether all recruits used in the analysis. We
will assess trials that included intention-to-treat analyses to ensure
this has been done correctly, ensuring participants have been in-
cluded even if they did not fully adhere to the protocol and that
it is possible to extract the appropriate data for these participants
from the results. We will use all trial data even if intention-to-treat
analysis was not conducted. However, we will look at which par-
ticipants dropped out or changed treatment to determine if these
relate to one specific group or are dispersed across all groups.
Assessment of heterogeneity
We will check for heterogeneity by examining:
• characteristics of the study;
• forest plot of results of the studies;
• results of the Chi2 test;
• results of the I2 statistic.
We will determine heterogeneity using the I2 statistic. We will
consider I2 greater than 50% as substantial heterogeneity. If I2 is
greater than50%,wewill explore the individual trial characteristics
to identify potential sources of heterogeneity, using pre-planned
subgroup analyses. If I2 is less than or equal to 50%, we will used
the fixed-effect model for our meta-analyses.
Assessment of reporting biases
We will assess reporting biases as detailed in the Assessment of risk
of bias in included studies section. If 10 or more studies are in-
cluded in analysis, we will use a funnel plot, examining for asym-
metry in the assessment of reporting bias.
Wewill attempt to avoid reporting biases by using a comprehensive
search strategy which includes searching for unpublished studies,
and searching trials registers. We will carry out sensitivity analyses
to explore the effect of publication type. We will evaluate studies
for selective reporting of outcomes. Where there is an online pro-
tocol for the trial, we will obtain this and compare the reported
study outcomes from the publication to the protocol.
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Data synthesis
We will combine results to produce a single summary measure
using a random-effects model unless there are few trials (three or
less), in which case we will use a fixed-effect model. If there is
substantial heterogeneity (I2 > 50%), we will not combine results,
unless the effect estimates are all in the same direction. If we do
not produce a single summary measure, we will do a narrative
summary of the trial results. If multi-arm studies are included,
we will ensure that the analysis of multiple intervention groups
avoids arbitrary omission of relevant groups and double-counting
of participants.
Subgroup analysis and investigation of heterogeneity
For effect of timing, we will compare the effect of interventions
at different times points of early intervention (Intervention given
within one month of eye movement disorder onset) versus late
intervention (intervention given after onemonth of eyemovement
disorder onset).
For effect of treatment, we will compare the interventions against
each other as outlined above with the different types of treat-
ment (restitutive, compensatory, substitutive and pharmacologi-
cal) forming a framework for subgroup analysis.
If I2 is greater than 50%, we will explore the individual trial char-
acteristics to identify potential sources of heterogeneity, using pre-
planned subgroup analyses. We intend to explore heterogeneity
by subgroup analyses to investigate the effect on the primary out-
come of:
• gender (male, female);
• type of acquired brain injury (trauma, surgery, stroke, brain
tumour, infection, inflammation, ischaemia);
• side of brain injury (left, right, bilateral);
• type of eye movement disorder (III, IV & VI nerve palsy,
reduced fixation/gaze holding, saccadic problems, smooth
pursuit problems, strabismus, nystagmus, reduced convergence,
conjugate deviation, skew deviation);
• deviation of eye movement (horizontal, vertical, torsional);
• severity of eye movement disorder (slight, small, moderate,
marked, paralysis, paresis, monocular, binocular);
• type of treatment (e.g. for compensative interventions -
saccadic eye movement, activities of daily living training; for
substitutive interventions - prisms, patches, environmental
modifications);
• variable timing of treatment (e.g. within one week of onset
and upwards).
We will use an established method for subgroup analyses (Deeks
2001).
Sensitivity analysis
We intend to carry out sensitivity analyses to explore the effect of
the following methodological features.
• Allocation concealment: we will re-analyse data, excluding
trials with inadequate or unclear allocation concealment.
• Masking of outcome assessor: we will re-analyse data,
excluding trials without or with unclear masking of outcome
assessor.
• Missing outcome data: we will re-analyse data, excluding
trials with inadequate or unclear methods of dealing with
missing outcome data.
• Other bias: we will re-analyse data, exclude trials assessed to
have other bias, or are unclear as to whether they have other bias.
• Publication type (peer-reviewed journal, conference
abstract/proceedings, doctoral dissertation): we will re-analyse
data including only those trials from peer-reviewed journals.
Methods for future updates
If trials become available in the future we will include them in this
review using the methods for the primary review. We will update
our systematic review every two years.
Summary of findings
We will include a ’Summary of findings’ table according to rec-
ommendations described in Chapter 11 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Schünemann 2011a
). We will include results for one population group, indicate the
intervention and the comparison intervention, include seven or
fewer patient-important outcomes (e.g. symptoms, adverse events,
quality of life), describe the outcomes (e.g. scale, scores, follow-
up), indicate the number of participants and studies for each out-
come, present at least one baseline risk for each dichotomous out-
come (e.g. study population or median/medium risk) and base-
line scores for continuous outcomes (if appropriate), summarise
the intervention effect (if appropriate), and include a measure of
the quality of the body of evidence (independent grading of ev-
idence by two authors) as per the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) guidelines
described in Chapter 12 of the Cochrane Handbook for Systematic
Reviews of Interventions (Schünemann 2011b).
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Brain Injuries] explode all trees
#2 brain near/2 injur*
#3 ABI or TBI or non TB
#4 #1 or #2 or #3
#5 MeSH descriptor: [Eye] explode all trees
#6 MeSH descriptor: [Visually Impaired Persons] explode all trees
#7 MeSH descriptor: [Ocular Physiological Processes] explode all trees
#8 MeSH descriptor: [Diagnostic Techniques, Ophthalmological] explode all trees
#9 MeSH descriptor: [Optometry] explode all trees
#10 MeSH descriptor: [Orthoptics] explode all trees
#11 MeSH descriptor: [Eye Diseases] this term only
#12 MeSH descriptor: [Vision Disorders] this term only
#13 MeSH descriptor: [Eye Manifestations] this term only
#14 MeSH descriptor: [Blindness] this term only
#15 MeSH descriptor: [Diplopia] explode all trees
#16 MeSH descriptor: [Vision, Binocular] this term only
#17 MeSH descriptor: [Vision, Monocular] this term only
#18 MeSH descriptor: [Visual Acuity] explode all trees
#19 MeSH descriptor: [Visual Fields] this term only
#20 MeSH descriptor: [Vision, Low] this term only
#21 MeSH descriptor: [Visual Field Tests] explode all trees
#22 MeSH descriptor: [Ophthalmology] this term only
#23 MeSH descriptor: [Vision Screening] this term only
#24 MeSH descriptor: [Eye Diseases, Hereditary] explode all trees
#25 MeSH descriptor: [Ocular Motility Disorders] explode all trees
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#26 MeSH descriptor: [Optic Nerve Diseases] explode all trees
#27 MeSH descriptor: [Orbital Diseases] explode all trees
#28 MeSH descriptor: [Pupil Disorders] explode all trees
#29 MeSH descriptor: [Refractive Errors] explode all trees
#30 MeSH descriptor: [Blindness, Cortical] explode all trees
#31 MeSH descriptor: [Hemianopsia] explode all trees
#32 MeSH descriptor: [Scotoma] this term only
#33 MeSH descriptor: [Abducens Nerve] this term only
#34 MeSH descriptor: [Oculomotor Nerve] this term only
#35 MeSH descriptor: [Trochlear Nerve] this term only
#36 nystagmus or smooth pursuit or saccades or depth perception or stereopsis or ophthalmol* or optic nerve
#37 gaze* near/2 (deficit* or palsy or disorder*)
#38 ocular near/2 (muscle* or align*)
#39 esotropi* or exotropi* or hypertropi* or hypotropi* or cyclotropi*
#40 intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation
#41(visual* or vision or eye or eyes or eyesight or sight) near/5 (problem* or disorder* or impair* or disabilit* or loss or disease* or
defect* or manifestation* or screening or test* or examination*)
#42 reading near/2 (difficult* or impair*)
#43 hemianop* or blindness or low vision or refractive errors or scotoma or diplopia or optometr* or ocular or orthoptic*
#44 oscillopsia or visual tracking or fresnel prism*
#45 III or IV or VI or third or fourth or sixth near/3 nerve palsy
#46 (#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #22 or #23 or #24
or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #40 or #41 or #43 or #44 or #45)
#47 #4 and #46
Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.









11. 9 not (9 and 10)
12. 8 not 11
13. exp brain injuries/
14. (brain adj2 injur$).tw.
15. (ABI or TBI or non TBI).tw.
16. or/13-15
17. exp Eye/
18. exp Visually Impaired Persons/
19. exp Ocular Physiological Processes/
20. exp Diagnostic Techniques, Ophthalmological/
21. exp Optometry/
22. exp Orthoptics/
23. exp Eye Diseases/
24. exp Vision Disorders/
25. exp Eye Manifestations/
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30. exp Visual Acuity/
31. Visual Fields/
32. Vision, Low/
33. exp Visual Field Tests/
34. Ophthalmology/
35. Vision Screening/
36. Eye Diseases, Hereditary/
37. exp Ocular Motility Disorders/
38. exp Optic Nerve Diseases/
39. Enophthalmos/
40. exp Pupil Disorders/







48. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve$).tw.
49. (gaze$ adj2 (deficit$ or palsy or disorder$)).tw.
50. (ocular adj2 (muscle$ or align$)).tw.
51. (esotropi$ or exotropi$ or hypertropi$ or hypotropi$ or cyclotropi$).tw.
52. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation).tw.
53. ((visual$ or vision or eye or eyes or eyesight or sight) adj3 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
54. (reading adj2 (difficult$ or impair$)).tw.
55. (hemianop$ or blindness or low vision or refractive errors or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
56. (oscillopsia or visual tracking or fresnel prism$).tw.
57. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
58. or/17-57
59. 16 and 58
60. 12 and 59
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
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13. (clin$ adj3 trial$).tw.




18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp brain injury/
34. (brain adj2 injur$).tw.
35. (ABI or TBI or non TBI).tw.
36. or/33-35
37. eye/
38. exp visual system function/




43. exp visual disorder/
44. exp eye movement disorder/




49. exp optic nerve disease/
50. exp cranial nerve/
51. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve$).tw.
52. (gaze$ adj2 (deficit$ or palsy or disorder$)).tw.
53. (ocular adj2 (muscle$ or align$)).tw.
54. (esotropi$ or exotropi$ or hypertropi$ or hypotropi$ or cyclotropi$).tw.
55. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation).tw.
56. ((visual$ or vision or eye or eyes or eyesight or sight) adj3 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
57. (reading adj2 (difficult$ or impair$)).tw.
58. (hemianop$ or blindness or low vision or refractive errors or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
59. (oscillopsia or visual tracking or fresnel prism$).tw.
60. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
61. or/37-60
62. 36 and 61
63. 32 and 62
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Appendix 4. CINAHL (EBSCO) search strategy
S56 S12 AND S55
S55 S16 AND S54
S54 S51 or S52 or S53
S53 S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51
S52 S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40
S51 S17 or S18 or S19 S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30
S50 nerve palsy
S49 oscillopsia or visual tracking or fresnel prism*
S48 hemianop* or blindness or low vision or refractive errors or scotoma or diplopia or optometr* or ocular or orthoptic*
S47 reading N2 (difficult* or impair*)
S46 (visual* or vision or eye or eyes or eyesight or sight) N5 (problem* or disorder* or impair* or disabilit* or loss or disease* or defect*
or manifestation* or screening or test* or examination*)
S45 intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation
S44 esotropi* or exotropi* or hypertropi* or hypotropi* or cyclotropi*
S43 ocular N2 (muscle* or align*)
S42 gaze* N2 (deficit* or palsy or disorder*)
S41 nystagmus or smooth pursuit or saccades or depth perception or stereopsis or ophthalmol* or optic nerve
S40 (MH “Trochlear Nerve”) OR (MH “Trochlear Nerve Diseases”)
S39 (MH “Abducens Nerve Diseases+”) OR (MM “Abducens Nerve”)
S38 (MM “Refractive Errors+”)
S37 (MH “Pupil Disorders+”)
S36 (MH “Orbital Diseases+”)
S35 (MH “Optic Nerve Diseases+”)
S34 (MM “Ocular Motility Disorders”)
S33 (MM “Eye Diseases, Hereditary”)
S32 (MM “Ophthalmology”)
S31 (MH “Vision Tests+”)
S30 (MH “Visual Perception+”)
S29 (MM “Visual Fields”)
S28 (MH “Visual Acuity”)
S27 (MH “Depth Perception”)
S26 (MH “Vision, Subnormal”)
S25 (MM “Diplopia”)
S24 (MH “Blindness+”)
S23 (MH “Eye Manifestations+”)
S22 (MH “Vision Disorders+”)
S21 (MH “Eye Diseases+”)
S20 (MM “Optometry”)
S19 (MH “Diagnosis, Eye+”)
S18 (MH “Rehabilitation of Vision Impaired+”)
S17 (MH “Eye+”)
S16 S13 or S14 or S15
S15 ABI or TBI or non TBI
S14 brain N2 injur*
S13 (MH “Brain Injuries+”)
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S11 TX allocat* random*
S10 (MM “Quantitative Studies”)
S9 (MM “Placebos”)
S8 TX placebo*
S7 TX random* allocat*
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S6 (MM “Random Assignment”)
S5 TX randomi* control* trial*
S4 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl*
n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S3 TX clinic* n1 trial*
S2 PT Clinical trial
S1 (MH “Clinical Trials+”)
Appendix 5. AMED (OvidSP) search strategy
1. “Randomized controlled trials”/
2. prospective studies/





8. ((singl$ or doubl$) adj3 (blind$ or mask$)).tw.
9. or/1-8
10. brain injuries/
11. (brain adj2 injur$).tw.











23. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve$).tw.
24. (gaze$ adj2 (deficit$ or palsy or disorder$)).tw.
25. (ocular adj2 (muscle$ or align$)).tw.
26. (esotropi$ or exotropi$ or hypertropi$ or hypotropi$ or cyclotropi$).tw.
27. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation).tw.
28. ((visual$ or vision or eye or eyes or eyesight or sight) adj3 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
29. (reading adj2 (difficult$ or impair$)).tw.
30. (hemianop$ or blindness or low vision or refractive errors or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
31. (oscillopsia or visual tracking or fresnel prism$).tw.
32. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
33. or/14-33
34. 13 and 33
35. 9 and 34
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Appendix 6. PsychINFO (OvidSP) search strategy
1. exp Treatment Effectiveness Evaluation/






8. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).tw.
9. (factorial$ or allocat$ or assign$ or volunteer$).tw.
10. (crossover$ or cross over$).tw.
11. (quasi adj (experimental or random$)).tw.
12. (control$ adj3 (trial$ or study or studies or group$)).tw.
13. or/1-12
14. exp Brain Damage/
15. exp Traumatic Brain Injury/
16. (ABI or TBI or non TB).tw.
17. exp Head Injuries/
18. or/14-17
19. exp Eye Disorders/
20. exp Eye Fixation/
21. exp “Pupil (Eye)”/






28. exp Binocular Vision/
29. exp Eye Convergence/
30. exp Color Perception/
31. exp Visual Acuity/
32. exp Visual Field/
33. exp Ophthalmology/
34. exp Ophthalmologic Examination/
35. exp Hemianopia/
36. exp Abducens Nerve/
37. exp Cranial Nerves/
38. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve$).tw.
39. (gaze$ adj2 (deficit$ or palsy or disorder$)).tw.
40. (ocular adj2 (muscle$ or align$)).tw.
41. (esotropi$ or exotropi$ or hypertropi$ or hypotropi$ or cyclotropi$).tw.
42. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation).tw.
43. ((visual$ or vision or eye or eyes or eyesight or sight) adj3 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
44. (reading adj2 (difficult$ or impair$)).tw.
45. (hemianop$ or blindness or low vision or refractive errors or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
46. (oscillopsia or visual tracking or fresnel prism$).tw.
47. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
48. or/19-47
49. 18 and 48
50. 13 and 49
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Appendix 7. Dissertations and Theses (PQDT) database
Keywords (dissertation topic) = brain injury
Appendix 8. PsycBITE database
PsycBITE was searched using the following options from the search interface:
Neurological Group = Traumatic Brain Injury (TBI) /Head Injury
Method = Randomised Controlled Trials
Target area = Literacy/Numeracy OR Visual Field Loss OR Community Re-entry
Appendix 9. metaRegister of Controlled Trials search strategy
brain injury AND (vision or eye or ocular or nystagmus or strabismus or gaze or diplopia or reading)
Appendix 10. ClinicalTrials.gov search strategy
Brain Injury AND (Vision OR Eye OR Ocular OR Nystagmus OR Strabismus OR Gaze OR Diplopia OR Reading)
Appendix 11. Health Services Research Projects in Progress
(“Brain Injury” AND (Vision OR Eye OR Ocular OR Nystagmus OR Strabismus OR Gaze OR Diplopia OR Reading))
Appendix 12. National Eye Institute Clinical Studies Database
brain AND vision
Appendix 13. ICTRP search strategy
Brain Injury = Condition AND Vision OR Eye OR Ocular OR Nystagmus OR Strabismus OR Gaze OR Diplopia OR Reading =
Intervention
Appendix 14. Standardised headings for included studies table
Headings in table in RevMan Proposed subheadings
Methods Study design • Parallel group RCT i.e. people randomised to treatment
• Paired eye or intra-individual RCT i.e. eyes randomised to
treatment
• Cluster RCT i.e. communities randomised to treatment
• Cross-over RCT
• Other
Eyes • One eye included in study
◦ Indicating how the eye was selected
• Two eyes included in study, both eyes received same treatment
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(Continued)
◦ Indicating how data were analysed (best/worst/average/
both and adjusted for within person correlation/both and not
adjusted for within person correlation
◦ Indicating if a mixture of one eye and two eyes were used
• Two eyes included in study, eyes received different treatments
(pair matched)











Eye movement disorders Description of the type of eye movement disorder (III, IV, and VI
cranial nerve palsy, reduced fixation, gaze holding, gaze palsy, saccadic
problems, smooth pursuit problems, strabismus, nystagmus, reduced
convergence or divergence, conjugate deviation, skew deviation), the
deviation of eye movement (horizontal, vertical, torsional), and the
severity of eye movement disorder (slight, small, moderate, marked;
paralysis, paresis; monocular, binocular)
Acquired brain injury Description of type of brain injury, natural history, side of brain injury
Interventions Intervention
Comparator
We will provide a description of interventions given to each treat-
ment group including, if relevant, the duration, intensity, frequency,
or dose. We will classify the type of intervention as restitution, com-
pensation, pharmacological or substitution, type of brain injury, type
of eye movement disorder, and the type of control as no treatment,
placebo, control, or standard care. We will document the professional
background of the person providing the intervention (e.g. ophthal-
mologist, orthoptist)
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(Continued)
Outcomes List We will document the primary and secondary outcomes relevant to
this review as listed in the Types of outcome measures section. Specifi-
cally, we will document measurements showing change in angle of de-
viation and/or extent of eye movement range, measurement of binoc-
ular single vision, documentation of patient-reported symptoms, doc-
umentation of questionnaires and adverse events. If a study has used
a number of different methods of measuring the same outcome (e.g.
prisms and degrees for measurement of ocular deviation), we will note
each method to be used for any subsequent analysis
Notes Date conducted Indicating specific dates of recruitment of participants mm/yr to mm/
yr
Sources of funding
Declaration of interest Indicating any declarations of interest among the primary researchers
Other Wewill record any important confounding variables. If a study includes
more than two intervention groups, we will also record the method of
including these groups in any subsequent analysis
C O N T R I B U T I O N S O F A U T H O R S
Fiona Rowe will lead this protocol, provide methodological expertise and write the protocol.
Carmel Noonan will act as a second reviewer and provide content expertise.
Sonia MacDiarmid, Kathryn Jarvis, Caroline Dodridge, Tallat Maan, Lorraine North, Marta Garcia-Finana, Claire Howard and Helen
Rodgers will provide additional content expertise, will read and comment on final drafts of the protocol.
D E C L A R A T I O N S O F I N T E R E S T
Fiona Rowe is an NIHR Research Fellow and has received funding from the NIHR to support research relating to visual problems after
stroke (including this Cochrane Review).
The work presented here represents the view of the authors and not necessarily those of the funding bodies.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
NIHR have funded the research fellowship programme that encompasses this Review.
Richard Wormald (Co-ordinating Editor for the Cochrane Eyes and Vision Group) acknowledges financial support for his Cochrane
Eyes and Vision Group research sessions from the Department of Health through the award made by the NIHR to Moorfields Eye
Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for
Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS or the
Department of Health.
19Interventions for eye movement disorders due to acquired brain injury (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
